Across TCGA pan-cancer cohorts, MTOR Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MTOR data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher MTOR Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MTOR expression acts as an unfavorable survival marker, although some lineages such as UCEC and KIRC show a favorable association.
THYM, UCEC, and UVM are the cancer types where MTOR Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.